Revvity buys ACD/Labs to expand its Signals Software Capabilities

US-based Revvity, Inc. has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets.

This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to accelerate scientific innovation. The transaction is expected to close late in Q4 2025.

ACD/Labs brings deep expertise in supporting analytical and process chemistry within pharmaceutical and chemical R&D workflows. Its industry-leading tools help scientists identify and characterize molecules, monitor purity and quality, and deliver robust production processes.

Together, Revvity Signals and ACD/Labs will provide comprehensive support across the scientific workflow—from discovery and development to scale-up and manufacturing— giving scientists the ability to interpret, manage, and act on complex data with greater speed and confidence.

ACD/Labs’ industry-leading tools include:

• Spectrus® Platform: advanced spectral analysis
• Percepta® Platform: AI-driven molecular property and ADMET prediction
• Other specialized applications: parallel and high-throughput experimentation (Katalyst D2D®), pharmaceutical chemistry, manufacturing, and controls decision support (Luminata®), and enterprise analytical data management (ADMS)